Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EGFRvIII CAR T cells in Recurrent Glioblastoma
NCT02844062Phase 1Unknown
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-EGFRvIII CAR-T cells in glioblastoma multiforme (GBM), sponsored by Beijing Sanbo Brain Hospital. Primary endpoint: Safety of infusion of autologous anti-EGFRvIII CAR T cells at 2 years. Status: unknown.
02
Drugs
anti-EGFRvIII CAR-T cells
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02844062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844062.